{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:39:19Z","timestamp":1792201159882,"version":"4.4.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pancreatic cancer (PC) is highly lethal because of its immunosuppressive tumor microenvironment and resistance to immunotherapy. This study explored the role of NAT10-mediated N4-acetylcytidine (ac4C) RNA modification in pancreatic cancer progression and immune evasion. NAT10 (N-acetyltransferase 10) is overexpressed in pancreatic cancer tissues and correlates with poor prognosis. Mechanistically, NAT10 stabilizes ETS2 mRNA through ac4C acetylation, forming a positive feedback loop that upregulates NAT10 and PD-L1, thereby suppressing CD8\u2009+\u2009T cell infiltration and promoting immune evasion. In addition, NAT10 stabilizes KRT8 mRNA via ac4C acetylation, which drives cancer cell proliferation and metastasis. Single-cell RNA sequencing analysis revealed enhanced interactions between pancreatic cancer epithelial cells with high NAT10 and KRT8 expression, and T cells, thereby providing new insights into the immune microenvironment. In vivo, NAT10 knockdown significantly inhibited tumor growth, enhanced CD8\u2009+\u2009T cell infiltration, and reduced lung metastasis. Notably, combination therapy with an NAT10 inhibitor and anti-PD-L1 antibody demonstrated superior antitumor efficacy compared to monotherapy. In conclusion, NAT10 promotes pancreatic cancer progression and immune evasion by regulating the ETS2-PD-L1 axis and stabilizing KRT8 mRNA, highlighting its potential as a therapeutic target for overcoming immunotherapy resistance.<\/jats:p>","DOI":"10.1038\/s41419-025-08156-0","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:12:31Z","timestamp":1762521151000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Targeting the ac4C \u2018Writer\u2019 NAT10 enhances pancreatic cancer immunotherapy via dual modulation of CD8+ T cells and tumor cells"],"prefix":"10.1038","volume":"16","author":[{"given":"Leisheng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enhong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongjie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youzhao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4454-3432","authenticated-orcid":false,"given":"Shudong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3956-681X","authenticated-orcid":false,"given":"Yong","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8663-8176","authenticated-orcid":false,"given":"Hao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"8156_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA: A Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA: A Cancer J Clin"},{"key":"8156_CR2","doi-asserted-by":"crossref","unstructured":"Wood LD, Canto MI, Jaffee EM, Simeone DM. Pancreatic cancer: pathogenesis, screening, diagnosis and treatment. Gastroenterology. 2022;163:386-402","DOI":"10.1053\/j.gastro.2022.03.056"},{"key":"8156_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41575-023-00840-w","volume":"21","author":"ZI Hu","year":"2024","unstructured":"Hu ZI, O\u2019Reilly EM. Therapeutic developments in pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2024;21:7\u201324.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"8156_CR4","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1200\/JCO.21.02616","volume":"40","author":"NA Ullman","year":"2022","unstructured":"Ullman NA, Burchard PR, Dunne RF, Linehan DC. Immunologic strategies in pancreatic cancer: making cold tumors hot. J Clin Oncol. 2022;40:2789\u2013805.","journal-title":"J Clin Oncol"},{"key":"8156_CR5","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/cac2.12539","volume":"44","author":"G Khosravi","year":"2024","unstructured":"Khosravi G, Mostafavi S, Bastan Sanaz, Ebrahimi N, Gharibvand RoyaSafari, Eskandari N. Immunologic tumor microenvironment modulators for turning cold tumors hot. Cancer Commun. 2024;44:521\u201353.","journal-title":"Cancer Commun"},{"key":"8156_CR6","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1158\/2159-8290.CD-22-0876","volume":"13","author":"C Falcomat\u00e0","year":"2023","unstructured":"Falcomat\u00e0 C, B\u00e4rthel S, Schneider G, Rad R, Schmidt-Supprian M, Saur D. Context-specific determinants of the immunosuppressive tumor microenvironment in pancreatic cancer. Cancer Discov. 2023;13:278\u201397.","journal-title":"Cancer Discov"},{"key":"8156_CR7","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/s41416-023-02361-4","volume":"129","author":"MM Wang","year":"2023","unstructured":"Wang MM, Coupland SE, Aittokallio T, Figueiredo CR. Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities. Br J Cancer. 2023;129:1212\u201324.","journal-title":"Br J Cancer"},{"key":"8156_CR8","doi-asserted-by":"crossref","unstructured":"Yang Q, Lei X, He J, Peng Y, Zhang Y, Ling R, et al. N4-Acetylcytidine drives glycolysis addiction in gastric cancer via NAT10\/SEPT9\/HIF-1\u03b1 positive feedback loop. Adv Sci. 2023;10:e2300898.","DOI":"10.1002\/advs.202300898"},{"key":"8156_CR9","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1002\/cac2.12363","volume":"42","author":"X Zheng","year":"2022","unstructured":"Zheng X, Wang Q, Zhou Y, Zhang D, Geng Y, Hu W, et al. N-acetyltransferase 10 promotes colon cancer progression by inhibiting ferroptosis through N4-acetylation and stabilization of ferroptosis suppressor protein 1 (FSP1) mRNA. Cancer Commun. 2022;42:1347\u201366.","journal-title":"Cancer Commun"},{"key":"8156_CR10","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1021\/acs.accounts.3c00673","volume":"57","author":"S Thalalla Gamage","year":"2024","unstructured":"Thalalla Gamage S, Howpay Manage S, Sas-Chen A, Nir R, Burkhart BW, Jhulki I. Cytidine Acetylation across the Tree of Life. Acc Chem Res. 2024;57:338\u201348.","journal-title":"Acc Chem Res"},{"key":"8156_CR11","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1016\/j.cell.2018.10.030","volume":"175","author":"D Arango","year":"2018","unstructured":"Arango D, Sturgill D, Alhusaini N, Dillman AA, Sweet TJ, Hanson G, et al. Acetylation of Cytidine in mRNA Promotes Translation Efficiency. Cell. 2018;175:1872\u20131886.e24.","journal-title":"Cell"},{"key":"8156_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.738","volume":"12","author":"G Wang","year":"2022","unstructured":"Wang G, Zhang M, Zhang Y, Xie Y, Zou J, Zhong J, et al. NAT10-mediated mRNA N4-acetylcytidine modification promotes bladder cancer progression. Clin Transl Med. 2022;12:e738.","journal-title":"Clin Transl Med"},{"key":"8156_CR13","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41392-021-00489-4","volume":"6","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Jing Y, Wang Y, Tang J, Zhu X, Jin WL, et al. NAT10 promotes gastric cancer metastasis via N4-acetylated COL5A1. Signal Transduct Target Ther. 2021;6:173.","journal-title":"Signal Transduct Target Ther"},{"key":"8156_CR14","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1002\/cac2.12363","volume":"42","author":"X Zheng","year":"2022","unstructured":"Zheng X, Wang Q, Zhou Y, Zhang D, Geng Y, Hu W, et al. N-acetyltransferase 10 promotes colon cancer progression by inhibiting ferroptosis through N4-acetylation and stabilization of ferroptosis suppressor protein 1 (FSP1) mRNA. Cancer Commun (Lond). 2022;42:1347\u201366.","journal-title":"Cancer Commun (Lond)"},{"key":"8156_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.127789","volume":"254","author":"L Wang","year":"2024","unstructured":"Wang L, Tao Y, Zhai J, Xue M, Zheng C, Hu H. The emerging roles of ac4C acetylation \u201cwriter\u201d NAT10 in tumorigenesis: A comprehensive review. Int J Biol Macromol. 2024;254:127789.","journal-title":"Int J Biol Macromol"},{"key":"8156_CR16","doi-asserted-by":"publisher","first-page":"108576","DOI":"10.1016\/j.pharmthera.2023.108576","volume":"253","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Lei Y, Dong Y, Chen S, Sun S, Zhou F, et al. Emerging roles of RNA ac4C modification and NAT10 in mammalian development and human diseases. Pharmacol Ther. 2023;253:108576\u20136.","journal-title":"Pharmacol Ther"},{"key":"8156_CR17","doi-asserted-by":"publisher","first-page":"113620","DOI":"10.1016\/j.yexcr.2023.113620","volume":"428","author":"G Zong","year":"2023","unstructured":"Zong G, Wang X, Guo X, Zhao Q, Wang C, Shen S, et al. NAT10-mediated AXL mRNA N4-acetylcytidine modification promotes pancreatic carcinoma progression. Exp Cell Res. 2023;428:113620.","journal-title":"Exp Cell Res"},{"key":"8156_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s10020-024-00780-4","volume":"30","author":"G Qin","year":"2024","unstructured":"Qin G, Bai F, Hu H, Zhang J, Zhan W, Wu Z, et al. Targeting the NAT10\/NPM1 axis abrogates PD-L1 expression and improves the response to immune checkpoint blockade therapy. Mol Med. 2024;30:13.","journal-title":"Mol Med"},{"key":"8156_CR19","doi-asserted-by":"crossref","unstructured":"Li K, Liu J, Yang X, Tu Z, Huang K, Zhu X. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy. Biosci Rep. 2021;41:BSR20212300.","DOI":"10.1042\/BSR20212300"},{"key":"8156_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202302705","volume":"10","author":"X Chen","year":"2023","unstructured":"Chen X, Hao Y, Liu Y, Zhong S, You Y, Ao K, et al. NAT10\/ac4C\/FOXP1 promotes malignant progression and facilitates immunosuppression by reprogramming glycolytic metabolism in cervical cancer. Adv Sci. 2023;10:e2302705.","journal-title":"Adv Sci"},{"key":"8156_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102227","volume":"101","author":"CL Gerard","year":"2021","unstructured":"Gerard CL, Delyon J, Wicky A, Homicsko K, Cuendet MA, Michielin O. Turning tumors from cold to inflamed to improve immunotherapy response. Cancer Treat Rev. 2021;101:102227.","journal-title":"Cancer Treat Rev"},{"key":"8156_CR22","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.immuni.2018.06.006","volume":"49","author":"J Li","year":"2018","unstructured":"Li J, Byrne KT, Yan F, Yamazoe T, Chen Z, Baslan T, et al. Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy. Immunity. 2018;49:178\u201393.e7.","journal-title":"Immunity"},{"key":"8156_CR23","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1053\/j.gastro.2018.12.038","volume":"156","author":"VP Balachandran","year":"2019","unstructured":"Balachandran VP, Beatty GL, Dougan SK. Broadening the impact of immunotherapy to pancreatic cancer: challenges and opportunities. Gastroenterology. 2019;156:2056\u201372.","journal-title":"Gastroenterology"},{"key":"8156_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1133166","volume":"14","author":"D Xu","year":"2023","unstructured":"Xu D, Huang K, Chen Y, Yang F, Xia C, Yang H. Immune response and drug therapy based on ac4C-modified gene in pancreatic cancer typing. Front Immunol. 2023;14:1133166.","journal-title":"Front Immunol"},{"key":"8156_CR25","doi-asserted-by":"publisher","first-page":"21.29.1","DOI":"10.1002\/0471142727.mb2129s109","volume":"109","author":"JD Buenrostro","year":"2015","unstructured":"Buenrostro JD, Wu B, Chang HY, Greenleaf WJ. ATAC-seq: A method for assaying chromatin accessibility genome-wide. Curr Protoc Mol Biol. 2015;109:21.29.1\u201321.29.9.","journal-title":"Curr Protoc Mol Biol"},{"key":"8156_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-47594-7","volume":"9","author":"W Zhao","year":"2019","unstructured":"Zhao W, Zhou Y, Cui Q, Zhou Y. PACES: prediction of N4-acetylcytidine (ac4C) modification sites in mRNA. Sci Rep. 2019;9:11112.","journal-title":"Sci Rep"},{"key":"8156_CR27","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1002\/cac2.12595","volume":"44","author":"H Liu","year":"2024","unstructured":"Liu H, Xu L, Yue S, Su H, Chen X, Liu Q, et al. Targeting N4-acetylcytidine suppresses hepatocellular carcinoma progression by repressing eEF2-mediated HMGB2 mRNA translation. Cancer Commun. 2024;44:1018\u201341.","journal-title":"Cancer Commun"},{"key":"8156_CR28","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41422-023-00793-4","volume":"33","author":"L Liao","year":"2023","unstructured":"Liao L, He Y, Li SJ, Yu XM, Liu ZC, Liang YY, et al. Lysine 2-hydroxyisobutyrylation of NAT10 promotes cancer metastasis in an ac4C-dependent manner. Cell Res. 2023;33:355\u201371.","journal-title":"Cell Res"},{"key":"8156_CR29","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/s13577-022-00848-5","volume":"36","author":"LY Zhang","year":"2023","unstructured":"Zhang LY, Tan Y, Luo XJ, Wu JF, Ni YR. The roles of ETS transcription factors in liver fibrosis. Hum Cell. 2023;36:528\u201339.","journal-title":"Hum Cell"},{"key":"8156_CR30","doi-asserted-by":"publisher","first-page":"4772","DOI":"10.3390\/ijms23094772","volume":"23","author":"E Khosh Kish","year":"2022","unstructured":"Khosh Kish E, Choudhry M, Gamallat Y, Buharideen SM, Bismar DD. TA. The Expression of Proto-Oncogene ETS-Related Gene (ERG) plays a central role in the oncogenic mechanism involved in the development and progression of prostate cancer. Int J Mol Sci. 2022;23:4772.","journal-title":"Int J Mol Sci"},{"key":"8156_CR31","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1016\/j.ejca.2005.08.013","volume":"41","author":"A Seth","year":"2005","unstructured":"Seth A, Watson DK. ETS transcription factors and their emerging roles in human cancer. Eur J Cancer. 2005;41:2462\u201378.","journal-title":"Eur J Cancer"},{"key":"8156_CR32","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1042\/CS20191174","volume":"134","author":"H Wang","year":"2020","unstructured":"Wang H, Huang R, Guo W, Qin X, Yang Z, Yuan Z, et al. RNA-binding protein CELF1 enhances cell migration, invasion, and chemoresistance by targeting ETS2 in colorectal cancer. Clin Sci. 2020;134:1973\u201390.","journal-title":"Clin Sci"},{"key":"8156_CR33","first-page":"853","volume":"9","author":"Y Ito","year":"2002","unstructured":"Ito Y, Miyoshi E, Takeda T, Sakon M, Ihara S, Tsujimoto M, et al. Ets-2 overexpression contributes to progression of pancreatic adenocarcinoma. Oncol Rep. 2002;9:853\u20137.","journal-title":"Oncol Rep"},{"key":"8156_CR34","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1038\/onc.2011.90","volume":"30","author":"J-S Zhang","year":"2011","unstructured":"Zhang J-S, Koenig A, Harrison A, Ugolkov AV, Fernandez-Zapico ME, Couch FJ, et al. Mutant K-Ras increases GSK-3\u03b2 gene expression via an ETS-p300 transcriptional complex in pancreatic cancer. Oncogene. 2011;30:3705\u201315.","journal-title":"Oncogene"},{"key":"8156_CR35","doi-asserted-by":"publisher","first-page":"4831","DOI":"10.1038\/sj.onc.1209494","volume":"25","author":"T Furukawa","year":"2006","unstructured":"Furukawa T, Kanai N, Shiwaku HO, Soga N, Uehara A, Horii A. AURKA is one of the downstream targets of MAPK1\/ERK2 in pancreatic cancer. Oncogene. 2006;25:4831\u20139.","journal-title":"Oncogene"},{"key":"8156_CR36","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.neo.2016.07.006","volume":"18","author":"JR Pitarresi","year":"2016","unstructured":"Pitarresi JR, Liu X, Sharma SM, Cuiti\u00f1o MC, Kladney RD, Mace TA, et al. Stromal ETS2 Regulates Chemokine production and immune cell recruitment during Acinar-to-Ductal Metaplasia. Neoplasia. 2016;18:541\u201352.","journal-title":"Neoplasia"},{"key":"8156_CR37","doi-asserted-by":"publisher","first-page":"5603","DOI":"10.3390\/ijms24065603","volume":"24","author":"EP Kalabusheva","year":"2023","unstructured":"Kalabusheva EP, Shtompel AS, Rippa AL, Ulianov SV, Razin SV, Vorotelyak EA. A Kaleidoscope of Keratin Gene Expression and the Mosaic of Its Regulatory Mechanisms. Int J Mol Sci. 2023;24:5603.","journal-title":"Int J Mol Sci"},{"key":"8156_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44184-0","volume":"14","author":"A Toth","year":"2023","unstructured":"Toth A, Kannan P, Snowball J, Kofron M, Wayman JA, Bridges JP, et al. Alveolar epithelial progenitor cells require Nkx2-1 to maintain progenitor-specific epigenomic state during lung homeostasis and regeneration. Nat Commun. 2023;14:8452.","journal-title":"Nat Commun"},{"key":"8156_CR39","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20193468","volume":"40","author":"W Wang","year":"2020","unstructured":"Wang W, He J, Lu H, Kong Q, Lin S. KRT8 and KRT19, associated with EMT, are hypomethylated and overexpressed in lung adenocarcinoma and link to unfavorable prognosis. Biosci Rep. 2020;40:BSR20193468.","journal-title":"Biosci Rep"},{"key":"8156_CR40","doi-asserted-by":"crossref","unstructured":"Han G, Sinjab A, Rahal Z, Lynch AM, Treekitkarnmongkol W, Liu Y, et al. An atlas of epithelial cell states and plasticity in lung adenocarcinoma. Nature. 2024;627:656\u201363.","DOI":"10.1038\/s41586-024-07113-9"},{"key":"8156_CR41","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/cas.13120","volume":"108","author":"J Fang","year":"2017","unstructured":"Fang J, Wang H, Liu Y, Ding F, Ni Y, Shao S. High KRT8 expression promotes tumor progression and metastasis of gastric cancer. Cancer Sci. 2017;108:178\u201386.","journal-title":"Cancer Sci"},{"key":"8156_CR42","doi-asserted-by":"crossref","unstructured":"Li K, Hong Y, Yu Y, Xie Z, Lv D, Wang C, et al. NAT10 Promotes Prostate Cancer Growth and Metastasis by Acetylating mRNAs of HMGA1 and KRT8. Adv Sci. 2024;11:e2310131.","DOI":"10.1002\/advs.202310131"},{"key":"8156_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202402244","volume":"11","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Tang Y, Wang Y, Xu J, Yang X, Liu M, et al. SIN3B Loss Heats up Cold Tumor Microenvironment to Boost Immunotherapy in Pancreatic Cancer. Adv Sci. 2024;11:e2402244.","journal-title":"Adv Sci"},{"key":"8156_CR44","doi-asserted-by":"crossref","unstructured":"Hartupee C, Nagalo BM, Chabu CY, Tesfay MZ, Coleman-Barnett J, West JT, et al. Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target. Front. Immun. 2024;15:1287459.","DOI":"10.3389\/fimmu.2024.1287459"},{"key":"8156_CR45","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1158\/1078-0432.CCR-22-0784","volume":"29","author":"G Micevic","year":"2023","unstructured":"Micevic G, Bosenberg MW, Yan Q. The crossroads of cancer epigenetics and immune checkpoint therapy. Clin Cancer Res. 2023;29:1173\u201382.","journal-title":"Clin Cancer Res"},{"key":"8156_CR46","doi-asserted-by":"publisher","first-page":"6573","DOI":"10.3390\/ijms23126573","volume":"23","author":"N Ma","year":"2022","unstructured":"Ma N, Liu H, Wu Y, Yao M, Zhang B. Inhibition of N-Acetyltransferase 10 suppresses the progression of prostate cancer through regulation of DNA replication. Int J Mol Sci. 2022;23:6573.","journal-title":"Int J Mol Sci"},{"key":"8156_CR47","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13046-022-02273-w","volume":"41","author":"L Liu","year":"2022","unstructured":"Liu L, Huang X, Shi F, Song J, Guo C, Yang J, et al. Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy. J Exp Clin Cancer Res. 2022;41:56.","journal-title":"J Exp Clin Cancer Res"},{"key":"8156_CR48","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.trecan.2018.04.001","volume":"4","author":"AH Morrison","year":"2018","unstructured":"Morrison AH, Byrne KT, Vonderheide RH. Immunotherapy and Prevention of Pancreatic Cancer. Trends Cancer. 2018;4:418\u201328.","journal-title":"Trends Cancer"},{"key":"8156_CR49","doi-asserted-by":"crossref","unstructured":"Zhang X, Huang X, Xu J, Li E, Lao M, Tang T, et al. NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1. Nat Commun. 2021;12:4536.","DOI":"10.1038\/s41467-021-24769-3"},{"key":"8156_CR50","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003982","volume":"10","author":"X Zhang","year":"2022","unstructured":"Zhang X, Lao M, Xu J, Duan Y, Yang H, Li M, et al. Combination cancer immunotherapy targeting TNFR2 and PD-1\/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors. J Immunother Cancer. 2022;10:e003982.","journal-title":"J Immunother Cancer"},{"key":"8156_CR51","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s13046-023-02868-x","volume":"42","author":"NL Wittwer","year":"2023","unstructured":"Wittwer NL, Brown MP, Liapis V, Staudacher AH. Antibody drug conjugates: hitting the mark in pancreatic cancer? J Exp Clin Cancer Res. 2023;42:280.","journal-title":"J Exp Clin Cancer Res"},{"key":"8156_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-021-02308-z","volume":"22","author":"J Yu","year":"2021","unstructured":"Yu J, Chai P, Xie M, Ge S, Ruan J, Fan X, et al. Histone lactylation drives oncogenesis by facilitating m6A reader protein YTHDF2 expression in ocular melanoma. Genome Biol. 2021;22:85.","journal-title":"Genome Biol"},{"key":"8156_CR53","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1136\/gutjnl-2022-328845","volume":"72","author":"Y Bao","year":"2023","unstructured":"Bao Y, Zhai J, Chen H, Wong CC, Liang C, Ding Y, et al. Targeting m6A reader YTHDF1 augments antitumour immunity and boosts anti-PD-1 efficacy in colorectal cancer. Gut. 2023;72:1497\u2013509.","journal-title":"Gut"},{"key":"8156_CR54","doi-asserted-by":"crossref","unstructured":"Mei Z, Shen Z, Pu J, Liu Q, Liu G, He X, et al. NAT10-mediated ac4C acetylation-driven m6A modification via involvement of YTHDC1-LDHA\/PFKM regulates glycolysis and promotes osteosarcoma. Cell commun signal. 2024;22:51.","DOI":"10.1186\/s12964-023-01321-y"},{"key":"8156_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.3666","volume":"26","author":"L Yang","year":"2024","unstructured":"Yang L, Huang Z, Deng Y, Zhang X, Lv Z, Huang H, et al. Characterization of the m6A\/m1A\/m5C\/m7G-related regulators on the prognosis and immune microenvironment of glioma by integrated analysis of scRNA-seq and bulk RNA-seq data. J Gene Med. 2024;26:e3666.","journal-title":"J Gene Med"},{"key":"8156_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25803-0","volume":"12","author":"H Song","year":"2021","unstructured":"Song H, Song J, Cheng M, Zheng M, Wang T, Tian S, et al. METTL3-mediated m6A RNA methylation promotes the anti-tumour immunity of natural killer cells. Nat Commun. 2021;12:5522.","journal-title":"Nat Commun"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08156-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08156-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08156-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T14:03:22Z","timestamp":1762524202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08156-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8156"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08156-0","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"1 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethics Committee of Jiangnan University Hospital and all participants provided informed consent prior to their involvement (Ethics Number: LS2024065). The animal experiments were approved by the Animal Ethics Committee of Jiangnan University (Approval Number: JN.No. 20231230c0320530[625]).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved the final manuscript and agree to its submission and publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"809"}}